Angiotensin II receptor type 1 autoantibodies promote endothelial microparticles formation through activating p38 MAPK pathway

Journal of Hypertension

Volumn 32, Issue 4, 2014, Pages 762-770

  Yang, Shijun ^a   Zhong, Qi ^b   Qiu, Zhihua ^a   Chen, Xiao ^a   Chen, Fen ^a   Mustafa, Khamis ^a   Ding, Dan ^a   Zhou, Yanzhao ^a   Lin, Jibin ^a   Yan, Sen ^a   Deng, Yihuan ^a   Wang, Min ^a   Zhou, Yingling ^b   Liao, Yuhua ^a   Zhou, Zihua ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Angiotensin II receptor type 1 autoantibody; Endothelial microparticle; Hypertension; P38 mitogenactivated protein kinase pathway

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; AUTOANTIBODY; CD31 ANTIGEN; GLYCOPROTEIN IB ALPHA; IMMUNOGLOBULIN G; LOSARTAN; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; AGTR1 PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE P38; 4 [4 (4 FLUOROPHENYL) 5 (2 METHOXY 4 PYRIMIDINYL) 1 IMIDAZOLYL]CYCLOHEXANOL; ANGIOTENSIN II RECEPTOR TYPE 1 AUTOANTIBODY; MITOGEN ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ADULT; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIAL MICROPARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; ESSENTIAL HYPERTENSION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIGNAL TRANSDUCTION; SUPERNATANT; THROMBOCYTE FREE PLASMA; THROMBOCYTE RICH PLASMA; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD; CYTOLOGY; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HYPERTENSION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; TIME; PROTEIN PHOSPHORYLATION;

ADULT; AUTOANTIBODIES; ENDOTHELIAL CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMANS; HYPERTENSION; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; NITRIC OXIDE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 1; TIME FACTORS;

EID: 84896276815     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000083     Document Type: Article

References (40)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370:591-603
2. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990; 323:22-27
3. Panza JA. Endothelial dysfunction in essential hypertension. Clin Cardiol 1997; 20:II-26
4. Dignat-George F, Boulanger CM. The many faces of endothelial microparticles. Arterioscl Thromb Vasc Biol 2011; 31:27-33
5. Horstman LL, Jy W, Jimenez JJ, Ahn YS. Endothelial microparticles as markers of endothelial dysfunction. Front Biosci 2004; 9:1118-1135
6. Nozaki T, Sugiyama S, Koga H, Sugamura K, Ohba K, Matsuzawa Y, et al. Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. J Am Coll Cardiol 2009; 54:601-608
7. Nozaki T, Sugiyama S, Sugamura K, Ohba K, Matsuzawa Y, Konishi M, et al. Prognostic value of endothelial microparticles in patients with heart failure. Eur J Heart Failure 2010; 12:1223-1228
8. Leroyer AS, Anfosso F, Lacroix R, Sabatier F, Simoncini S, Njock SM, et al. Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis. Thromb Haemostasis 2010; 104:456-463
9. Preston RA, Jy W, Jimenez JJ, Mauro LM, Horstman LL, Valle M, et al. Effects of severe hypertension on endothelial and platelet microparticles. Hypertension 2003; 41:211-217
10. Bernal-Mizrachi L, Jy W, Jimenez JJ, Pastor J, Mauro LM, Horstman LL, et al. High levels of circulating endothelial microparticles in patients with acute coronary syndromes. Am Heart J 2003; 145:962-970
11. Amabile N, Guerin AP, Leroyer A, Mallat Z, Nguyen C, Boddaert J, et al. Circulating endothelial microparticles are associated with vascular dysfunction in patients with end-stage renal failure. J Am Soc Nephrol 2005; 16:3381-3388
12. Fu ML, Herlitz H, Schulze W, Wallukat G, Micke P, Eftekhari P, et al. Autoantibodies against the angiotensin receptor (AT1) in patients with hypertension. J Hypertens 2000; 18:945-953
13. Liao Y-H, Wei Y-M, Wang M, Wang Z-H, Yuan H-T, Cheng L-X. Autoantibodies against AT1-receptor and alpha1-adrenergic receptor in patients with hypertension. Hypertens Res 2002; 25:641
14. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, et al. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 1999; 103:945-952
15. Wallukat G, Neichel D, Nissen E, Homuth V, Luft FC. Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia. Can J Physiol Pharmacol 2003; 81:79-83
16. Yang X, Wang F, Chang H, Zhang S, Yang L, Wang X, et al. Autoantibody against AT1 receptor from preeclamptic patients induces vasoconstriction through angiotensin receptor activation. J Hypertens 2008; 26:1629-1635
17. Sun YX, Zhang HY, Wei YM, Zhu F, Wang M, Liao YH. The mechanism of signal transduction during vascular smooth muscle cell proliferation induced by autoantibodies against angiotensin AT1 receptor from hypertension. Chinese Med J 2008; 121:43-48
18. Wang B, Liao Y-H, Zhou Z, Li L, Wei F, Wang M, et al. Arterial structural changes in rats immunized by AT1-receptor peptide. Heart Vessels 2005; 20:153-158
19. Burger D, Montezano AC, Nishigaki N, He Y, Carter A, Touyz RM. Endothelial microparticle formation by angiotensin II is mediated via Ang II receptor type I/NADPH oxidase/Rho kinase pathways targeted to lipid rafts. Arterioscl Thromb Vasc Biol 2011; 31:1898-1907
20. Wei F, Jia X-J, Yu S-Q, Gu Y, Wang L, Guo X-M, et al. Candesartan versus imidapril in hypertension: A randomised study to assess effects of anti-AT1 receptor autoantibodies. Heart 2011; 97:479-484
21. Baudin B, Bruneel A, Bosselut N, Vaubourdolle M. A protocol for isolation and culture of human umbilical vein endothelial cells. Nat Protocols 2007; 2:481-485
22. Chen F, Chen X, Qiu Z, Wang M, Yang S, Khamis M, et al. Functional analysis of a novel antagonistic antibody against the short epitope of the alpha1A-adrenergic receptor. Cardiovasc Res 2012; 93:280-290
23. Jy W, Horstman L, Jimenez J, Ahn Y. Measuring circulating cell-derived microparticles. J Thromb Haemostasis 2004; 2:1842-1843
24. Boulanger CM, Scoazec A, Ebrahimian T, Henry P, Mathieu E, Tedgui A, et al. Circulating microparticles from patients with myocardial infarction cause endothelial dysfunction. Circulation 2001; 104: 2649-2652
25. van Ierssel SH, Van Craenenbroeck EM, Conraads VM, Van Tendeloo VF, Vrints CJ, Jorens PG, et al. Flow cytometric detection of endothelial microparticles (EMP): Effects of centrifugation and storage alter with the phenotype studied. Thromb Res 2010; 125:332-339
26. van Ierssel SH, Hoymans VY, Van Craenenbroeck EM, Van Tendeloo VF, Vrints CJ, Jorens PG, et al. Endothelial microparticles (EMP) for the assessment of endothelial function: An in vitro and in vivo study on possible interference of plasma lipids. PLoS One 2012; 7:e31496
27. Faure V, Dou L, Sabatier F, Cerini C, Sampol J, Berland Y, et al. Elevation of circulating endothelial microparticles in patients with chronic renal failure. J Thromb Haemostasis 2006; 4:566-573
28. Angelot F, Seilles E, Biichlé S, Berda Y, Gaugler B, Plumas J, et al. Endothelial cell-derived microparticles induce plasmacytoid dendritic cell maturation: Potential implications in inflammatory diseases. Haematologica 2009; 94:1502-1512
29. Jansen F, Yang X, Hoyer FF, Paul K, Heiermann N, Becher MU, et al. Endothelial microparticle uptake in target cells is annexin i/phosphatidylserine receptor dependent and prevents apoptosis. Arterioscl Thromb Vasc Biol 2012; 32:1925-1935
30. Urbich C, Dernbach E, Aicher A, Zeiher AM, Dimmeler S. CD40 ligand inhibits endothelial cell migration by increasing production of endothelial reactive oxygen species. Circulation 2002; 106:981-986
31. Combes V, Simon AC, Grau GE, Arnoux D, Camoin L, Sabatier F, et al. In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with lupus anticoagulant. J Clin Invest 1999; 104:93-102
32. Wang JM, Wang Y, Huang JY, Yang Z, Chen L, Wang LC, et al. CReactive protein-induced endothelial microparticle generation in HUVECs is related to BH4-dependent NO formation. J Vasc Res 2007; 44:241-248
33. Sapet C, Simoncini S, Loriod B, Puthier D, Sampol J, Nguyen C, et al. Thrombin-induced endothelial microparticle generation: Identification of a novel pathway involving ROCK-II activation by caspase-2. Blood 2006; 108:1868-1876
34. Simak J, Holada K, Vostal JG. Release of annexin V-binding membrane microparticles from cultured human umbilical vein endothelial cells after treatment with camptothecin. BMC Cell Biol 2002; 3:11
35. Jimenez JJ, Jy W, Mauro LM, Soderland C, Horstman LL, Ahn YS. Endothelial cells release phenotypically and quantitatively distinct microparticles in activation and apoptosis. Thromb Res 2003; 109:175-180
36. Curtis A, Wilkinson P, Gui M, Gales T, Hu E, Edelberg J. p38 mitogenactivated protein kinase targets the production of proinflammatory endothelial microparticles. J Thromb Haemostasis 2009; 7:701-709
37. Bao W, Behm DJ, Nerurkar SS, Ao Z, Bentley R, Mirabile RC, et al. Effects of p38 MAPK Inhibitor on angiotensin II-dependent hypertension, organ damage, and superoxide anion production. J Cardiovasc Pharmacol 2007; 49:362-368
38. Deschesnes RG, Huot J, Valerie K, Landry J. Involvement of p38 in apoptosis-associated membrane blebbing and nuclear condensation. Mol Biol Cell 2001; 12:1569-1582
39. Sinning J-M, Losch J, Walenta K, Böhm M, Nickenig G, Werner N. Circulating CD31/Annexin V microparticles correlate with cardiovascular outcomes. Eur Heart J 2011; 32:2034-2041
40. Lee S-T, Chu K, Jung K-H, Kim J-M, Moon H-J, Bahn J-J, et al. Circulating CD62E microparticles and cardiovascular outcomes. PLoS One 2012; 7:e35713